Literature DB >> 11476728

Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects.

L Bankir1.   

Abstract

(1) Vasopressin (VP), or antidiuretic hormone, is secreted in response to either increases in plasma osmolality (very sensitive stimulus) or to decreases in plasma volume (less sensitive stimulus). Its normal plasma level is very low (about 1 pg/ml, i.e. 10(-12) M), close to the detection limit of present immunoassays, and distinct antidiuretic effects are observed after infusion of small undetectable amounts of VP. (2) This antidiuretic action results from three main effects of VP on principal cells of the collecting duct (CD) mediated by occupancy of peritubular V2 receptors. (i) Increase in water permeability along the entire CD (via AQP2). (ii) Increase in urea permeability in only the terminal inner medullary CD (via UT-A1). (iii) Stimulation of sodium reabsorption, mainly in the cortical and outer medullary CD (via ENaC). VP also acts on medullary vasculature (V1a receptors) to reduce blood flow to inner medulla without affecting blood flow to outer medulla. Besides these actions, all concurring to increase urine osmolality in different and additive ways, other VP effects, probably exerted through V1a receptors located on luminal membrane, tend to limit the antidiuretic effects of the hormone. They induce the formation of prostaglandins which reduce V2-dependent cAMP accumulation in these cells and thus partially inhibit all three V2 effects. (3) Because urine is first diluted along the nephron before being concentrated in the medulla, VP is required, not only for urine concentration, but first for re-equilibration of tubular fluid osmolality with plasma osmolality, a step taking place in the renal cortex, and achieved through the reabsorption of large quantities of water (more than what is subsequently reabsorbed in the medulla to concentrate urine). Accordingly, VP effects on urine flow-rate are not linear. Small changes in plasma VP in the low range of urine osmolality will induce wide changes in urinary flow-rate, whereas in the upper range of urine osmolality larger changes in plasma VP induce much more limited further reduction in urine flow-rate. (4) Most likely, the different effects of VP require different levels of VP concentration to occur and are thus recruited successively with progressive rise in VP secretion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11476728     DOI: 10.1016/s0008-6363(01)00328-5

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  71 in total

1.  Activation of ENaC by AVP contributes to the urinary concentrating mechanism and dilution of plasma.

Authors:  Elena Mironova; Yu Chen; Alan C Pao; Karl P Roos; Donald E Kohan; Vladislav Bugaj; James D Stockand
Journal:  Am J Physiol Renal Physiol       Date:  2014-11-12

2.  A novel vasopressin-induced transcript promotes MAP kinase activation and ENaC downregulation.

Authors:  Marie Nicod; Stéphanie Michlig; Marjorie Flahaut; Miguel Salinas; Nicole Fowler Jaeger; Jean-Daniel Horisberger; Bernard C Rossier; Dmitri Firsov
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

3.  Expression of type II hyaluronan-synthase gene in kidneys Wistar and Brattleboro rats with diabetes insipidus: effect of vasopressin and its analogues.

Authors:  N O Kabilova; A A Bondar; L N Ivanova
Journal:  Dokl Biochem Biophys       Date:  2009 Mar-Apr       Impact factor: 0.788

4.  Aldosterone requires vasopressin V1a receptors on intercalated cells to mediate acid-base homeostasis.

Authors:  Yuichiro Izumi; Kahori Hori; Yushi Nakayama; Miho Kimura; Yukiko Hasuike; Masayoshi Nanami; Yukimasa Kohda; Yoshinaga Otaki; Takahiro Kuragano; Masuo Obinata; Katsumasa Kawahara; Akito Tanoue; Kimio Tomita; Takeshi Nakanishi; Hiroshi Nonoguchi
Journal:  J Am Soc Nephrol       Date:  2011-03-17       Impact factor: 10.121

Review 5.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

6.  Urinary concentration and dilution in the aging kidney.

Authors:  Jeff M Sands
Journal:  Semin Nephrol       Date:  2009-11       Impact factor: 5.299

7.  Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease.

Authors:  Romina Mancinelli; Antonio Franchitto; Shannon Glaser; Antonella Vetuschi; Julie Venter; Roberta Sferra; Luigi Pannarale; Francesca Olivero; Guido Carpino; Gianfranco Alpini; Paolo Onori; Eugenio Gaudio
Journal:  Lab Invest       Date:  2016-08-29       Impact factor: 5.662

8.  The intercalated cells of the mouse kidney OMCD(is) are the target of the vasopressin V1a receptor axis for urinary acidification.

Authors:  Yukiko Yasuoka; Mizuka Kobayashi; Yuichi Sato; Ming Zhou; Hiroshi Abe; Hirotsugu Okamoto; Hiroshi Nonoguchi; Akito Tanoue; Katsumasa Kawahara
Journal:  Clin Exp Nephrol       Date:  2013-03-01       Impact factor: 2.801

9.  Modulation of aquaporin 2 expression in the kidney of young goats by changes in nitrogen intake.

Authors:  Kristin Elfers; Gerhard Breves; Alexandra S Muscher-Banse
Journal:  J Comp Physiol B       Date:  2014-08-06       Impact factor: 2.200

10.  Conivaptan and its role in the treatment of hyponatremia.

Authors:  Jalal K Ghali; Jareer O Farah; Suleiman Daifallah; Hassan A Zabalawi; Hammam D Zmily
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.